Voyager Therapeutics Surges 60% On License Deal With Pfizer

Shares of Voyager Therapeutics, Inc. (VYGR) surged over 60% on Wednesday morning after the company announced a license option deal with Pfizer (PFE) that could be valued up to $630 million.

VYGR is currently trading at $3.97, up $1.50 or 60.7287%, on the Nasdaq.

Voyager Therapeutics announced a license option agreement with Pfizer, a deal which fetches $30 million up front for Voyager, with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties.

Voyager is a gene therapy company developing treatments and next-generation adeno-associated virus (AAV) platform technologies.

Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager's TRACER platform and to exercise options to license capsids for exclusive use in Pfizer's development of AAV gene therapies incorporating two undisclosed transgenes, the companies stated.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT